Hester Biosciences sets Q2 and H1 FY27 investor call for 5 November

Board & Shareholder Meetings View source PDF Explain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹2190.00

prior close

₹2214.30

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 170sector+0.6%+1.3% vs sector

On the reaction day the stock moved 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.8

15m

+0.8

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9pendingpending+0.6+1.3

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hester Biosciences will hold a Q2 and H1 FY27 results conference call on 5 November 2026 at 2:00 p.m. IST, after announcing results for the quarter and six months ended 30 September 2026. CEO and Managing Director Rajiv Gandhi, Executive Director Priya Gandhi, and Chief Financial Officer Ashish Desai will participate. The notice provides joining details but no financial figures.

Likely market impact

The call offers access to management, but no numbers or guidance are disclosed. Stock impact will depend on results and management comments.